Unlike continuous BTK inhibitor therapy, using a BTK inhibitor as part of a time-limited combination regimen does not appear to select for resistance mutations. This crucial distinction means that a BTK inhibitor could potentially be used again effectively as a subsequent line of therapy if the patient relapses.
Abstract data from the BRUIN CLL-322 trial reveals that adding pirtobrutinib to a venetoclax-rituximab backbone provides a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously treated CLL, without a substantial increase in toxicity.
Despite a major trial using rituximab in its pirtobrutinib-venetoclax combination, experts note a strong clinical preference for obinutuzumab as the more effective anti-CD20 antibody in CLL. This suggests that in real-world practice, clinicians may substitute obinutuzumab, adapting the trial regimen for perceived superior efficacy.
An expert expresses a strong preference for time-limited CLL therapies over continuous maintenance treatments. The rationale is that getting patients into a deep remission and then off treatment entirely leads to a better overall experience and quality of life, even if they eventually relapse.
For high-risk CLL patients who progress after both covalent BTK inhibitors and venetoclax, pirtobrutinib is not just the next line of therapy. It is strategically used to achieve disease control, creating a window to prepare the patient for a more definitive and potentially curative CAR-T cell therapy.
Clinical trial experience shows that delaying the administration of obinutuzumab in an Acalabrutinib-Venetoclax-Obinutuzumab (AVO) triplet regimen improves patient tolerability. This sequencing strategy allows clinicians to enhance response with the antibody later, if needed, while minimizing upfront side effects.
CAR-T therapy involves a significant but finite period of acute toxicity (CRS, ICANS) that resolves within about a month. In contrast, bispecific antibodies can cause persistent, low-grade immune activation symptoms like fatigue and malaise that last for the entire duration of the continuous treatment.
New oral BTK degraders show impressive response rates of 60-80% in CLL patients who have failed both covalent and non-covalent BTK inhibitors. However, the critical unknown is the durability of these responses. Future long-term data will determine their ultimate place in the treatment landscape.
